Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) a...
How might the current market sentiment (70) influence investor sentiment or trading volume in the short term?
Is there any indication of changes in the company's cost structure or operating expenses that could affect margins?
What does the guidance imply about IRWD’s cash flow and profitability outlook for the remainder of 2025?
21 days ago